Zenas BioPharma Prices Concurrent $200M Convertible Notes and $100M Equity Offerings
ZBIO has more than doubled off its 52-week low of $6.11 on elevated volume (3.7× avg).
Summary
Zenas BioPharma priced concurrent public offerings of $200 million in convertible senior notes and 5 million shares of common stock at $20.00 per share, raising approximately $287.4 million in net proceeds to fund its pipeline and planned commercial launch.
Key Events · Financing and Capital Events · ZBIO
-
Convertible Notes Offering Priced
Zenas BioPharma priced $200 million aggregate principal amount of 2.50% convertible senior notes due 2032, with an initial conversion price of approximately $26.50 per share. Net proceeds from the notes are estimated at $193.7 million.
-
Concurrent Equity Offering Priced
The company priced a concurrent public offering of 5 million shares of common stock at $20.00 per share. This price represents a discount to the last reported sale price of $22.16 per share on March 26, 2026. Net proceeds from the equity offering are estimated at $93.7 million.
-
Significant Capital Raise
The combined offerings are expected to generate approximately $287.4 million in net proceeds (excluding over-allotment options), providing substantial capital for the company's operations.
-
Funding for Pipeline and Commercial Launch
Proceeds will support the planned U.S. commercial launch of obexelimab for IgG4-RD (if approved) and advance the development pipeline, including orelabrutinib Phase 3 trials and ZB021 Phase 1/2 clinical development, extending the financial runway into the third quarter of 2028.
Analysis · ZBIO · Life Sciences
This filing finalizes the terms and pricing of Zenas BioPharma's concurrent capital raise, which is substantial relative to its market capitalization. The equity offering was priced at a discount to the stock's closing price on March 26, 2026, leading to significant dilution for existing shareholders. While dilutive, this capital infusion is critical for the company, which previously disclosed a going concern warning, enabling the planned U.S. commercial launch of obexelimab for IgG4-RD and advancing its development pipeline. The market has already reacted negatively to the pricing, with the stock plummeting 19% following the announcement.
At the time of this filing, ZBIO was trading at $18.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $6.11 to $44.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.